Iron accumulation in mammary tumor suggests a tug of war between tumor and host for the microelement.

Iron is indispensable for the metabolism and proliferation of both normal and malignant cells. Recycling from senescent erythrocytes in the liver and spleen is critical for iron supply to all tissues. In the liver and spleen from MMTV-neu (erbB-2) mice bearing a mammary carcinoma, we noticed the scarcity of hemosiderin pigment and its abundance in the stroma of the tumor. Thus iron (III) was investigated with the Perls' reaction in tissues from normal and MMTV-neu mice. With respect to normal animals, in MMTV-neu mice, staining for iron was almost absent in the liver and scarce in the red pulp of the spleen. By contrast, iron was abundant in stromal and tumor cells in the invasion, angiogenic, necrotic and hemorrhagic regions and also in the interstitial fluid. These observations suggest that the tumor subverts iron recycling to its own advantage, by directly utilizing iron released from erythrocytes and dead tumor cells. Our findings are in keeping with the development of iron chelating drugs as chemotherapic agents.

[1]  Weinberg Ed The role of iron in cancer. , 1996 .

[2]  A. Harris,et al.  Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate. , 2006, Cancer Research.

[3]  M. Bissell,et al.  Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. , 2006, Annual review of cell and developmental biology.

[4]  G. Chiesa,et al.  Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer. , 2000, Cancer research.

[5]  M. Hentze,et al.  Balancing Acts Molecular Control of Mammalian Iron Metabolism , 2004, Cell.

[6]  D. Richardson,et al.  Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. , 2004, Blood.

[7]  H. Dvorak,et al.  Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. , 2003, The American journal of pathology.

[8]  D. Richardson,et al.  Competing pathways of iron chelation: Angiogenesis or anti‐tumor activity: Targeting different molecules to induce specific effects , 2004, International journal of cancer.

[9]  D. Richardson,et al.  A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics , 2006, Proceedings of the National Academy of Sciences.

[10]  D. Richardson,et al.  The role of iron in cell cycle progression and the proliferation of neoplastic cells. , 2002, Biochimica et biophysica acta.

[11]  R K Jain,et al.  Transport of molecules, particles, and cells in solid tumors. , 1999, Annual review of biomedical engineering.

[12]  A. Pearse Histochemistry: Theoretical and Applied , 1953 .

[13]  Maria Grazia Sacco,et al.  Stem cell recruitment and liver de-differentiation in MMTV-neu (ErbB-2) transgenic mice. , 2003, Anticancer research.

[14]  M. Gassmann,et al.  Regulating cellular oxygen sensing by hydroxylation. , 2006, Cardiovascular research.

[15]  S. Spicer,et al.  FERRITIN PARTICLES IN MACROPHAGES AND IN ASSOCIATED MAST CELLS , 1972, The Journal of cell biology.

[16]  T. Ganz,et al.  Regulation of iron acquisition and iron distribution in mammals. , 2006, Biochimica et biophysica acta.

[17]  D. Richardson Therapeutic potential of iron chelators in cancer therapy. , 2002, Advances in experimental medicine and biology.

[18]  B. L. O’dell Roles for iron and copper in connective tissue biosynthesis. , 1981, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[19]  P. Gullino,et al.  THE INTERSTITIAL FLUID OF SOLID TUMORS. , 1964, Cancer research.

[20]  E. Weinberg Iron Withholding as a Defense Strategy , 2005 .

[21]  A. H. Baggenstoss,et al.  Iron-storage diseases. , 1955, American journal of clinical pathology.

[22]  V. Bertone,et al.  Stroma formation in Ehrlich carcinoma. I. Oedema phase. A mitosis burst as an index of physiological reoxygenation? , 1991, Anticancer research.

[23]  E. Brunt,et al.  Pathology of Hepatic Iron Overload , 2005, Seminars in liver disease.

[24]  V. Bertone,et al.  Tumor interstitial fluid: misconsidered component of the internal milieu of a solid tumor. , 1997, Anticancer research.

[25]  J. Brock The physiology of lactoferrin. , 2002, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[26]  D. Richardson Iron and neoplasia: serum transferrin receptor and ferritin in prostate cancer. , 2004, Journal of Laboratory and Clinical Medicine.

[27]  T. Daniels,et al.  The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. , 2006, Clinical immunology.

[28]  E. D. Hager,et al.  Hyperthermia in Cancer Treatment: A Primer , 2006 .

[29]  K. Sandelin,et al.  Proteomic Characterization of the Interstitial Fluid Perfusing the Breast Tumor Microenvironment , 2004, Molecular & Cellular Proteomics.

[30]  F. A. Hoffman Metabolic Changes in Malignancy , 1989 .

[31]  F. Torti,et al.  The role of iron chelation in cancer therapy. , 2003, Current medicinal chemistry.